关键入组标准包括经组织学确诊为尿路上皮癌、临床诊断为非转移性膀胱癌(cT2-T4a,N0-1,M0)、适合根治性膀胱切除术(RC)+盆腔淋巴结清扫(PLND)、HER2有表达(IHC 1+/2+/3+)的患者。主要研究终点为病理完全缓解率(pCR),次要研究...
RC48-C017主要终点是pCR,次要终点包括病理应答率、安全性和耐受性。该研究纳入了既往未经治疗的MIBC患者,临床分期为cT2-T4aN0-1M0,适合并同意接受RC+PLND (根治性膀胱切除术+盆腔淋巴结清扫术)治疗,同时局部检测HER2表达IHC 点击免费查看完整报告 你可能感兴趣 医药行业跟踪报告:IO+ADC新时代系列二:K药+Padcev...
INTRODUCTION AND OBJECTIVES Previous studies demonstrate that pelvic lymph node dissection (PLND) provides more accurate staging during radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC). Further, increased node counts hav... CJ Stimson,SG Patel,HB Zaid,... - 《Journal of Urology》...
了既往未经治疗的MIBC患者,临床分期为cT2-T4aN0-1M0,适合并同意接受RC+PLND (根治性膀胱切除术+盆腔淋巴结清扫术)治疗,同时局部检测HER2表达IHC≥1+。患 者将首先接受2mg/kgRC48+3mg/kg特瑞普利单抗作为新辅助治疗,每2周一次,共6 个周期,随后在4周内进行RC+PLND,并最后接受3mg/kg特瑞普利单抗作为辅助治...
By the data cut-off date (Feb-2024), 29 pts (65.9%) completed RC + PLND. The pCR rate was 62.1% (18/29). The pathologic response rate was 75.9% (22/29). Common treatment-related adverse events (TRAEs) were mostly Grade 1 or 2, including alopecia (36.4%), alanine aminotransferase...